ReviewThe Lancet regional health. Western Pacific2023
Post-COVID cognitive dysfunction: current status and research recommendations for high risk population.
Review in The Lancet regional health. Western Pacific, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 51 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Brain fog with long covid and chemotherapy: systematic review and meta-analysis.BMJ mental health · 2025Pooled it
- Pooled it
- Research evidence on the management of the cognitive impairment component of the post-COVID condition: a qualitative systematic review.European psychiatry : the journal of the Association of European Psychiatrists · 2024Pooled it
- Cognitive behavioral therapy, exercise training, and cognitive remediation for patients with post-COVID-19 condition: protocol of an open-label randomized controlled trial.BMC psychology · 2025Trial
- A digital intervention for cognitive deficits following COVID-19: a randomized clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- Oxygen supplementation and cognitive function in long-COVID.PloS one · 2024Trial
- Herbal medicine (Kyungok-go) for fatigue in Long COVID patients: A prospective multicenter pilot study.Integrative medicine research · 2026Article
- Article
- Clinical and Inflammatory Predictors of Neurocognitive Decline in Long COVID: A Two-Year Longitudinal Study with Propensity Score Matching.Medicina (Kaunas, Lithuania) · 2026Observational
- Cognitive impairment in long-COVID: frequency, trajectories and risk factors in a cohort study from Italy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Post-COVID cognitive dysfunction in socioeconomically-vulnerable older adults: findings from a Brazilian cohort.Arquivos de neuro-psiquiatria · 2026Article
- Objectifying persistent subjective cognitive impairment following COVID-19 infection: cross-sectional data from an outpatient memory-clinic in Germany.European archives of psychiatry and clinical neuroscience · 2026Article
- Neurocognitive and Psychiatric Outcomes Following Mild to Moderate COVID-19: A Longitudinal Comparison of Alpha/Delta and Omicron Variants.Neuropsychiatric disease and treatment · 2026Article
- Acupuncture for cognitive functions in post-COVID-19 condition: study protocol of a three-armed, randomized controlled trial with multimodal MRI.Frontiers in medicine · 2026Article
- Dynamic multivariate patterns of brain structure-neuropsychiatric symptom associations in long COVID.Brain communications · 2026Article
- Venous thromboembolism at high altitude: mechanisms, risk stratification, and precision prevention.Frontiers in physiology · 2026Review
- Trends in cognitive impairment among older adults in China from 2002 to 2022: Evaluating the impact of the COVID-19 pandemic.The journal of prevention of Alzheimer's disease · 2026Article
- Long-Term Mental Health Evaluation After COVID-19: Insights From the CARDIO COVID 20-21 Registry.Journal of clinical medicine research · 2026Article
- Inflammation from mild COVID-19 results in persistent neurological and behavioral changes in rhesus macaques.Research square · 2025Article
- Treatment experiences, preferences, and expectations for cognitive impairments in long COVID among Chinese young and older adults: a constructivist grounded theory study.BMC medicine · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-COVID cognitive dysfunction (PCCD) is a condition in which patients with a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, usually three months from the onset, exhibit subsequent cognitive impairment in various cognitive domains, and cannot be explained by an alternative diagnosis. While our knowledge of the risk factors and management strategy of PCCD is still incomplete, it is necessary to integrate current epidemiology, diagnosis and treatment evidence, and form consensus criteria to better understand this disease to improve disease management. Identifying the risk factors and vulnerable population of PCCD and providing reliable strategies for effective prevention and management is urgently needed. In this paper, we reviewed epidemiology, diagnostic markers, risk factors and available treatments on the disease, formed research recommendation framework for vulnerable population, under the background of post-COVID period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.